NIH Reporter #5R01CA266100-05

NCI/NIH Research Grant for APE2 Nuclease Role in DNA Repair and HR-Deficient Cancer

This opportunity is a research grant solicitation from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), focused on DNA repair mechanisms in cancer research. - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH) - Eligible Applicants: - Research institutions (e.g., University of Colorado, Boulder) - Products/Services Requested: - Research into the function of the APE2 nuclease during DNA repair by alternative end-joining - Study of APE2's role in homologous recombination (HR)-deficient cancer cells - Notable Requirements: - Focus on mechanisms of DNA repair and therapeutic targeting in HR-deficient cancer - No specific OEMs, commercial products, or equipment specified - Standard NIH grant application process applies - Estimated Grant Value: - $351,029 - No unique license, classification, or equipment requirements specified

Description

This is a research grant opportunity from the NIH/NCI focusing on DNA repair mechanisms related to homologous recombination deficiency in cancer cells. The project aims to characterize the APE2 nuclease's role in alternative end-joining pathways and its potential as a therapeutic target. The grant is intended to support research on the function of APE2 nuclease during DNA repair and its implications in HR-deficient cells. The opportunity is open for applications and follows the standard NIH grant application format.

View original listing